SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 4, 2024, between REGEN BIOPHARMA, INC, a Nevada corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (the “Investor”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • Nevada
AGREEMENT BY AND BETWEEN KCL THERAPEUTICS, INC. AND ONCOLOGY PHARMA INC.License Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • California
THIS LICENSE AGREEMENT, including the exhibits referred to herein and attached hereto (the “Agreement”), effective as of April 7, 2021 (the “Effective Date”), is made and entered into by and between KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen BioPharma Inc. (“Licensor”) and Oncology Pharma, Inc., a Nevada corporation (“Licensee”). Licensor and Licensee may be referred to in this Agreement each as a “Party” or collectively as the “Parties.”
10% PROMISSORY NOTESecurity Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • Delaware
THIS IS A 10% PROMISSORY NOTE of Regen Biopharma, Inc., a Nevada corporation (the “Company”), having its principal place of business at 4700 Spring Street, Suite 304, La Mesa, California 91942 (this “Note”), which represents a duly authorized and validly issued debt of the Company.
AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC.License Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations
THIS LICENSE AGREEMENT, including the exhibits referred to herein and attached hereto (the “Agreement”), effective as of June 23, 2015 (the “Effective Date”), is made and entered into by and between Regen BioPharma Inc., an Nevada corporation (“Licensor”) and Zander Therapeutics Inc., a Nevada corporation (“Licensee”). Licensor and Licensee may be referred to in this Agreement each as a “Party” or collectively as the “Parties.”
LICENSE ASSIGNMENT AND CONSENT AGREEMENTLicense Assignment Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations
THIS LICENSE ASSIGNMENT AND CONSENT AGREEMENT (this “Agreement”), is entered into as of December 17, 2018, by and among Zander Therapeutics, Inc. ( “Licensee”), Regen Biopharma, Inc. (“Licensor”) and KCL Therapeutics, Inc. (“Assignee”)
